The COX-2 inhibitors: new analgesic and anti-inflammatory drugs

Dental clinics of North America

Volumn 46, Issue 4, 2002, Pages 679-690

  Khan, Asma A ^a,b   Dionne, Raymond A ^b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; LACTONE; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; ROFECOXIB; SULFONE;

DIGESTIVE SYSTEM; DRUG ANTAGONISM; DRUG COST; DRUG EFFECT; ECONOMICS; FACE PAIN; HUMAN; POSTOPERATIVE PAIN; REVIEW; RISK FACTOR; SAFETY;

ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DRUG COSTS; FACIAL PAIN; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PAIN, POSTOPERATIVE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS; SAFETY; SULFONES;

EID: 0036777309     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-8532(02)00032-0     Document Type: Review

References (45)

1. S.M. Gordon R.A. Dionne J. Brahim Blockade of peripheral neuronal barrage reduces postoperative pain Pain 70 1997 209 215
2. R.A. Dionne S.M. Gordon L.M. McCullagh Assessment of clinical needs for anesthesia and sedation in the general population J Am Dent Assoc 129 1998 167 173
3. J. Kremer From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal J Rheumatol 27 Suppl 60 2000 9 12
4. G. Singh G. Triadafilopoulos Epidemeology of NSAID induced gastrointestinal complications J Rheumatol 26 1999 18 24
5. J.L. Carson B.L. Strom M.L. Morse The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs Arch Int Med 147 1987 1054 1059
6. E.V. Hersh P.A. Moore G. Ross Over-the-counter analgesics and antipyretics: a critical assessment Clin Ther 22 2000 500 548
7. J.R. Vane Y.S. Bakhle R.M. Botting Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120
8. T.D. Penning J.J. Talley S.R. Berteshaw Synthesis and biological evaluation of the 1,5′diarypyraziol class of cyclooxygenase inhibitors: identification of 4-{5-(4-Methylphenyl)-3-(trifloromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-68735, celecoxib) J Med Chem 40 1997 1347 1365
9. Schwartz B, Hurley SM, Hubbard RC, et al. A pilot study of the platelet effects of SC-58635, a novel COX-2 inhibitor. ILAR Congress of Rheumatology; 1997. p. 159.
10. A.A. Khan R.A. Dionne N.F. Capra In vivo selectivity of a selective cyclooxygenase-2 inhibitors in the oral surgery model Clin Pharmacol Ther 72 2002 44 49
11. R.C. Hubbard D.R. Jasper M.J. Nugent SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model J Invest Med 44 1996 293A
12. A.J. Matheson D.P. Figgit Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis Drugs 61 2001 833 865
13. J. Brown B.W. Morrisson S. Christensen MK-0966 50 mg versus ibuprofen 400 mg in post-surgical dental pain [abstract] Clin Pharmacol Ther 645 1999 118
14. J.F. Fricke B.W. Morrison S. Fite MK-966 versus naproxen sodium 550 mg in post-surgical dental pain [abstract] Clin Pharmacol Ther 645 1999 119
15. K. Malmstrom S. Daniels P. Kotey Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in post-operative dental pain: a randomized placebo- and active-comparator controlled clinical trial Clin Ther 21 1999 1653 1663
16. J. Fricke J. Varkalis S. Zwillich R. Adler E. Forester D.P. Recker Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery Am J Ther 9 2 2002 89 97
17. B.W. Morrison S. Christensen W. Yuan J. Brown S. Amlani B. Seidenberg Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial Clin Ther 21 6 1999 943 953
18. S.S. Reuben N.R. Connelly Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery Anesth Analg 91 2000 1221 1225
19. S.S. Reuben R. Fingeroth R. Krushell H. Maciolek Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty J Arthroplasty 17 1 2002 26 31
20. E.L. Truelove The chemotherapeutic management of chronic and persistent orofacial pain Dent Clin N Am 38 1994 669 688
21. E.J. Singer Y. Sharav R. Dubner The efficacy of diazepam and ibuprofen in the treatment of chronic myofascial orofacial pain Pain Suppl 4 1987 S83
22. S.M. Gordon M.T. Montgomery D. Jones Comparative efficacy of piroxicam versus placebo for temperomandibular pain [abstract] J Dent Res 69 1990 218
23. S.F. Dworkin E.L. Truelove J.J. Bonica Facial and head pain caused by myofascial and temperomandibular disorders J.J. Bonica The management of pain 1990 Lea and Febiger Philadelphia 727 745
24. C. McNeill Temperomandibular disorders 1993 Quintessence Chicago p. 87
25. R. Pownall N.J. Pickvance Does treatment timing matter? A double blind crossover study of ibuprofen 2400 mg per day in different dosage schedules in treatment of lower back pain Br J Clin Pract 39 1985 267 275
26. J.S. Walker G. Levy Effect of multiple dosing on the analgesic action of diflunisal in rats Life Sci 46 1990 737 742
27. K. Yamagata K.I. Andreasson W.E. Kaufmann C.A. Barnes P.F. Worley Expression of mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids Neuron 11 1993 371 386
28. R.C. Harris J.A. McKanna Y. Akai Renal effects of cyclooygenase-2 selective inhibitors J Clin Invest 93 1994 2504 2510
29. H. Lim R.A. Gupta W. Ma Cyclo-oxygenase-2 derived prostacyclin mediates embryo implantation in the mouse via PPARδ Genes Dev 13 1999 1561 1574
30. C.W. Houchen W.F. Stenson S.M. Cohn Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury Am J Physiol Gastrointest Liver Physiol 279 2000 G858 G865
31. D.W. Gilroy P.R. Colville-Nash D. Willis Inducible cyclooxygenase may have anti-inflammatory properties Nat Med 5 1999 698 701
32. S. Mizuno C. Sakamoto K. Matsuda Induction of cyclooxygeanse-2 in gastric mucosal ulcers and its inhibition by the specific agonist delays healing in mice Gastroenterology 112 1997 387 397
33. B.K. Reuter S. Asfaha A. Buret Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2 J Clin Invest 98 1996 2076 2085
34. R.D. Newberry W.F. Stenson R.G. Lorenz Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen Nat Med 5 1999 900 906
35. F.E. Silverstein G. Faich J.L. Goldstein Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial JAMA 284 2000 1247 1255
36. Okie S. Missing data on celebrex. The Washington Post: A11, August 5, 2001.
37. C. Bombardier L. Laine A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
38. M.J. Langman D.M. Jensen D.J. Watson Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1999 1929 1933
39. J.K. Hennan J. Huang T.D. Barret Effects of selective COX-2 inhibition on vascular responses and thrombosis in the canine coronary arteries Circulation 104 2001 820 825
40. S. Wallberg-Jonsson H. Johansson M.L. Ohman Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset J Rheumatol 26 1999 2562 2571
41. J. Rossat M. Maillard J. Nussberger Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects Clin Pharmacol Ther 66 1999 76 84
42. A. Whelton Renal aspects of treatment with conventional non-steroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors Am J Med 110 Suppl 1 2001 S33 S42
43. P.J. Desjardins E.H. Grossman M.E. Kuss S. Talwalker S. Dhadda D. Baum The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively Anesth Analg 93 3 2001 721 727
44. S.E. Daniels E.H. Grossman M.E. Kuss A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac in a post-surgery pain model Clin Ther 23 2001 1018 1031
45. K. Wakitani H. Tazaki Matsushita JTE-522 selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissue Inflam Res 49 2000 117 122